This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2015 Aug 15:61 Suppl 1:S32-3.

doi: 10.1093/cid/civ460.

The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens

Dakshina Chilukuri¹, Owen McMaster², Kimberly Bergman¹, Philip Colangelo¹, Kerry Snow², Joseph G Toerner²

Affiliations

Affiliations

¹ Center for Drug Evaluation and Research, Office of Clinical Pharmacology, Office of Translational Sciences.
² Office of New Drugs, US Food and Drug Administration, Silver Spring, Maryland.

PMID: 26224770
DOI: 10.1093/cid/civ460

The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens

Dakshina Chilukuri et al. Clin Infect Dis. 2015.

. 2015 Aug 15:61 Suppl 1:S32-3.

doi: 10.1093/cid/civ460.

Authors

Dakshina Chilukuri¹, Owen McMaster², Kimberly Bergman¹, Philip Colangelo¹, Kerry Snow², Joseph G Toerner²

Affiliations

¹ Center for Drug Evaluation and Research, Office of Clinical Pharmacology, Office of Translational Sciences.
² Office of New Drugs, US Food and Drug Administration, Silver Spring, Maryland.

PMID: 26224770
DOI: 10.1093/cid/civ460

No abstract available

Keywords: antimycobacterial; in vitro; tuberculosis.

PubMed Disclaimer

Similar articles

Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
Cavaleri M, Manolis E. Cavaleri M, et al. Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S1-4. doi: 10.1093/cid/civ484. Clin Infect Dis. 2015. PMID: 26224766
Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
Pasipanodya JG, Nuermberger E, Romero K, Hanna D, Gumbo T. Pasipanodya JG, et al. Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S10-7. doi: 10.1093/cid/civ425. Clin Infect Dis. 2015. PMID: 26224767
Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.
Gumbo T, Pasipanodya JG, Romero K, Hanna D, Nuermberger E. Gumbo T, et al. Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S25-31. doi: 10.1093/cid/civ427. Clin Infect Dis. 2015. PMID: 26224769
Nonclinical models for antituberculosis drug development: a landscape analysis.
Gumbo T, Lenaerts AJ, Hanna D, Romero K, Nuermberger E. Gumbo T, et al. J Infect Dis. 2015 Jun 15;211 Suppl 3:S83-95. doi: 10.1093/infdis/jiv183. J Infect Dis. 2015. PMID: 26009617 Review.
Drug resistance in tuberculosis.
al-Orainey IO. al-Orainey IO. J Chemother. 1990 Jun;2(3):147-51. doi: 10.1080/1120009x.1990.11739007. J Chemother. 1990. PMID: 2116504 Review.

See all similar articles

Cited by

Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.
Deshpande D, Srivastava S, Chapagain M, Magombedze G, Martin KR, Cirrincione KN, Lee PS, Koeuth T, Dheda K, Gumbo T. Deshpande D, et al. Sci Adv. 2017 Aug 30;3(8):e1701102. doi: 10.1126/sciadv.1701102. eCollection 2017 Aug. Sci Adv. 2017. PMID: 28875168 Free PMC article.
Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development.
Gumbo T, Srivastava S, Deshpande D, Pasipanodya JG, Berg A, Romero K, Hermann D, Hanna D. Gumbo T, et al. J Antimicrob Chemother. 2023 Apr 3;78(4):953-964. doi: 10.1093/jac/dkad029. J Antimicrob Chemother. 2023. PMID: 36794692 Free PMC article.
Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis.
Mallikaarjun S, Chapagain ML, Sasaki T, Hariguchi N, Deshpande D, Srivastava S, Berg A, Hirota K, Inoue Y, Matsumoto M, Hafkin J, Geiter L, Wang X, Gumbo T, Liu Y. Mallikaarjun S, et al. Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01207-20. doi: 10.1128/AAC.01207-20. Print 2020 Dec 16. Antimicrob Agents Chemother. 2020. PMID: 33106263 Free PMC article.
Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.
Deshpande D, Pasipanodya JG, Mpagama SG, Srivastava S, Bendet P, Koeuth T, Lee PS, Heysell SK, Gumbo T. Deshpande D, et al. Clin Infect Dis. 2018 Nov 28;67(suppl_3):S317-S326. doi: 10.1093/cid/ciy609. Clin Infect Dis. 2018. PMID: 30496457 Free PMC article.
Shortening Tuberculosis Treatment With Fluoroquinolones: Lost in Translation?
Lanoix JP, Chaisson RE, Nuermberger EL. Lanoix JP, et al. Clin Infect Dis. 2016 Feb 15;62(4):484-90. doi: 10.1093/cid/civ911. Epub 2015 Nov 1. Clin Infect Dis. 2016. PMID: 26527614 Free PMC article.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information